TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT
Phase 4
- Conditions
- Acute Ischemic Stroke
- Interventions
- Combination Product: Urapidil Hydrochloride Injection
- Registration Number
- NCT03529149
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Brief Summary
Investigators hypothesized that the precise regulation of blood pressure based on the changes of cerebral blood flow parameters under TCD monitoring can better improve the state of cerebral blood flow, reduce the risk of early neurological deterioration and improve the prognosis of the patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
- 18 years of age or older;
- accept EVT treatment within 6 hours of symptoms onset;
- In selected patients with AIS within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria..
- In selected patients with AIS within 6 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria.
Exclusion Criteria
- Pre - onset mRS>2;
- severe dementia;
- threatening life diseases (such as malignant tumor, etc.);
- non acute ischemic cerebrovascular disease patients undergoing selective intravascular treatment;
- related sound window closure can not be monitoring with TCD.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Guideline blood pressure control Urapidil Hydrochloride Injection Control blood pressure according to guidelines Accurate blood pressure control Urapidil Hydrochloride Injection Implementing accurate blood pressure management under TCD monitoring
- Primary Outcome Measures
Name Time Method early neurological deterioration 72 hours the incidence of 72 hours in National Institute of Health stroke scale increased more than 4 points or National Institute of Health stroke scale Ia score more than 1 points
- Secondary Outcome Measures
Name Time Method prognosis of nerve function 3 months prognosis of nerve function use Modified Rankin Scale,0\~3 is good prognosis and 4\~6 is poor prognosis.
Trial Locations
- Locations (1)
Xuanwu Hospital
🇨🇳Beijing, Beijing, China